NCT06373744已完成不适用
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 597 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 597
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:
How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females, >18 years old;
- •Diagnosed with advanced breast cancer when using metronomic chemotherapy;
- •At least one clinical evaluation, including physical examination and imaging, according to the instructions of the supervising physician during the use of metronomic chemotherapy. Examinations include ultrasound, computed tomography, and magnetic resonance imaging;
- •Metronomic chemotherapy can be used alone, and patients who use it in combination with other drugs can also be included;
- •The clinical pathological information that needs to be collected is complete.
排除标准
- •Taking the drug for less than 2 weeks;
- •losing follow-up after taking the therapy;
- •The patient's breast cancer was still in the early stage when taking the therapy.
研究组 & 干预措施
metronomic chemotherapy
Patients with advanced breast cancer who received metronomic chemotherapy.
干预措施: cyclophosphamide , methotrexate , vinorelbine ,capecitabine (Drug)
结局指标
主要结局
Progression free survival
时间窗: Baseline up to approximately 20 months
Time from randomization to the first documentation of objective tumor progression or to death due to any cause without documented progression
次要结局
- Overall Survival(Baseline until death (up to approximately 40 months))
- Disease Control Rate(Baseline up to approximately 20 months)
- Objective Response Rate(Baseline up to approximately 20 months)
研究者
wang shusen
Dr
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancersadvance and recurrent gynecological cancerJPRN-UMIN000016438Saitama Medical University International Medical Center30
进行中（未招募）
1 期
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
招募中
2 期
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer PatientsAdvanced Breast CancerNCT04304352European Institute of Oncology162
进行中（未招募）
1 期
Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumorEUCTR2021-002540-67-FRCentre Oscar Lambret28
Unknown
2 期
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast CancerBreast CancerNCT00687648National Cancer Centre, Singapore70